Tags

Type your tag names separated by a space and hit enter

Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.
Cell Mol Immunol. 2006 Dec; 3(6):459-65.CM

Abstract

In order to investigate immunogenicity in the induction of humoral and cellular immune responses, severe acute respiratory syndrome associated coronavirus (SARS-CoV)-N gene recombinant replication-defective adenoviral vector, rAd-N, was generated and immunized BALB/c mice in a pcDNA3.1-N prime-rAd-N boost regimen. After humoral and cellular immune response detection, different levels of SARS-CoV N protein specific antibodies and interferon-gamma (IFN-gamma) secretion are shown compared to controls. The humoral immune response was induced more effectively by the DNA priming and recombinant adenovirus boosting regimen. There is a significant difference between heterogeneous and homologous vaccinations. The heterogeneous combinations were all higher than those of the homologous combinations in the induction of anti-N antibody response. Among the three heterogeneous combinations, pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/rAd-N induced the strongest antibody response. In the induction of IFN-gamma production, the homologous combination of rAd-N/rAd-N/rAd-N/rAd-N was significantly stronger than that of pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N, but was relatively weaker than the heterogeneous combination of pcDAN3.1-N/pcDAN3.1-N/pcDAN3.1-N/rAd-N. This combination was a most efficient immunization regimen in induction of SARS-CoV-N-specific (IFN-gamma) secretion just as the antibody response. These results suggest that DNA immunization followed by recombinant adenovirus boosting could be used as a potential SARS-CoV vaccine.

Authors+Show Affiliations

Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17257500

Citation

Ma, Chunling, et al. "Comparative Immunization in BALB/c Mice With Recombinant Replication-defective Adenovirus Vector and DNA Plasmid Expressing a SARS-CoV Nucleocapsid Protein Gene." Cellular & Molecular Immunology, vol. 3, no. 6, 2006, pp. 459-65.
Ma C, Yao K, Zhou F, et al. Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. Cell Mol Immunol. 2006;3(6):459-65.
Ma, C., Yao, K., Zhou, F., & Zhu, M. (2006). Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. Cellular & Molecular Immunology, 3(6), 459-65.
Ma C, et al. Comparative Immunization in BALB/c Mice With Recombinant Replication-defective Adenovirus Vector and DNA Plasmid Expressing a SARS-CoV Nucleocapsid Protein Gene. Cell Mol Immunol. 2006;3(6):459-65. PubMed PMID: 17257500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. AU - Ma,Chunling, AU - Yao,Kun, AU - Zhou,Feng, AU - Zhu,Minsheng, PY - 2007/1/30/pubmed PY - 2007/3/21/medline PY - 2007/1/30/entrez SP - 459 EP - 65 JF - Cellular & molecular immunology JO - Cell Mol Immunol VL - 3 IS - 6 N2 - In order to investigate immunogenicity in the induction of humoral and cellular immune responses, severe acute respiratory syndrome associated coronavirus (SARS-CoV)-N gene recombinant replication-defective adenoviral vector, rAd-N, was generated and immunized BALB/c mice in a pcDNA3.1-N prime-rAd-N boost regimen. After humoral and cellular immune response detection, different levels of SARS-CoV N protein specific antibodies and interferon-gamma (IFN-gamma) secretion are shown compared to controls. The humoral immune response was induced more effectively by the DNA priming and recombinant adenovirus boosting regimen. There is a significant difference between heterogeneous and homologous vaccinations. The heterogeneous combinations were all higher than those of the homologous combinations in the induction of anti-N antibody response. Among the three heterogeneous combinations, pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/rAd-N induced the strongest antibody response. In the induction of IFN-gamma production, the homologous combination of rAd-N/rAd-N/rAd-N/rAd-N was significantly stronger than that of pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N, but was relatively weaker than the heterogeneous combination of pcDAN3.1-N/pcDAN3.1-N/pcDAN3.1-N/rAd-N. This combination was a most efficient immunization regimen in induction of SARS-CoV-N-specific (IFN-gamma) secretion just as the antibody response. These results suggest that DNA immunization followed by recombinant adenovirus boosting could be used as a potential SARS-CoV vaccine. SN - 1672-7681 UR - https://www.unboundmedicine.com/medline/citation/17257500/Comparative_immunization_in_BALB/c_mice_with_recombinant_replication_defective_adenovirus_vector_and_DNA_plasmid_expressing_a_SARS_CoV_nucleocapsid_protein_gene_ L2 - http://www.cmi.ustc.edu.cn/3/6/459.pdf DB - PRIME DP - Unbound Medicine ER -